167 related articles for article (PubMed ID: 28506695)
1. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
[No Abstract] [Full Text] [Related]
3. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
[TBL] [Abstract][Full Text] [Related]
4. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
[TBL] [Abstract][Full Text] [Related]
5. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
[TBL] [Abstract][Full Text] [Related]
6. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
7. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
[TBL] [Abstract][Full Text] [Related]
8. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199
[TBL] [Abstract][Full Text] [Related]
9. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
[TBL] [Abstract][Full Text] [Related]
12. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
13. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
15. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Lindblad O; Kazi JU; Rönnstrand L; Sun J
Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
[TBL] [Abstract][Full Text] [Related]
16. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.
Kohl TM; Schnittger S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 Apr; 105(8):3319-21. PubMed ID: 15618474
[TBL] [Abstract][Full Text] [Related]
17. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Larizza L; Magnani I; Beghini A
Leuk Lymphoma; 2005 Feb; 46(2):247-55. PubMed ID: 15621809
[TBL] [Abstract][Full Text] [Related]
18. Cytological and spectroscopic characteristics of c-KIT N822K mutation in core binding factor acute myeloid leukemia cells.
Chen Y; Wang L; Lin X; Zhang Q; Xu Y; Lin D; Xu J; Feng S; Hu J
J Biophotonics; 2020 Aug; 13(8):e202000103. PubMed ID: 32390317
[TBL] [Abstract][Full Text] [Related]
19. KIT
Phung B; Kazi JU; Lundby A; Bergsteinsdottir K; Sun J; Goding CR; Jönsson G; Olsen JV; Steingrímsson E; Rönnstrand L
Mol Cancer Res; 2017 Sep; 15(9):1265-1274. PubMed ID: 28584020
[TBL] [Abstract][Full Text] [Related]
20. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]